Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).
Integrating the patient's perspective has become an increasingly important component of adverse event reporting. The National Cancer Institute has developed a Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™). This instrument has been translated into German and linguistically validated; however, its quantitative measurement properties have not been evaluated.



A German language survey that included 31 PRO-CTCAE items, as well as the EORTC QLQ-C30 and the Oral Mucositis Daily Questionnaire (OMDQ), was distributed at 10 cancer treatment settings in Germany and Austria. Item quality was assessed by analysis of acceptability and comprehensibility. Reliability was evaluated by using Cronbach's' alpha and validity by principal components analysis (PCA), multitrait-multimethod matrix (MTMM) and known groups validity techniques.



Of 660 surveys distributed to the study centres, 271 were returned (return rate 41%), and data from 262 were available for analysis. Participants' median age was 59.7 years, and 69.5% of the patients were female. Analysis of item quality supported the comprehensibility of the 31 PRO-CTCAE items. Reliability was very good; Cronbach's' alpha correlation coefficients were >0.9 for almost all item clusters. Construct validity of the PRO-CTCAE core item set was shown by identifying 10 conceptually meaningful item clusters via PCA. Moreover, construct validity was confirmed by the MTMM: monotrait-heteromethod comparison showed 100% high correlation, whereas heterotrait-monomethod comparison indicated 0% high correlation. Known groups validity was supported; PRO-CTCAE scores were significantly lower for those with impaired versus preserved health-related quality of life.



A set of 31 items drawn from the German PRO-CTCAE item library demonstrated favourable measurement properties. These findings add to the body of evidence that PRO-CTCAE provides a rigorous method to capture patient self-reports of symptomatic toxicity for use in cancer clinical trials.
Institute of Pharmacy, Clinical Pharmacy, University of Bonn, Bonn, Germany.
V
V
Hagelstein
Institute of Pharmacy, Clinical Pharmacy, University of Bonn, Bonn, Germany.
I
I
Ortland
Institute of Pharmacy, Clinical Pharmacy, University of Bonn, Bonn, Germany.
A
A
Wilmer
Division of Cancer Control and Population Sciences, Outcomes Research Branch, National Cancer Institute, Rockville, USA.
S A
SA
Mitchell
Institute of Pharmacy, Clinical Pharmacy, University of Bonn, Bonn, Germany u.jaehde@uni-bonn.de.
U
U
Jaehde
D016907:Adverse Drug Reaction Reporting Systems; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology* / Q000473:pathology; D005260:Female; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000453:epidemiology*; D063868:Patient Outcome Assessment; D011788:Quality of Life; D011795:Surveys and Questionnaires
D000970:Antineoplastic Agents
German; PRO-CTCAE; cancer; patient-reported outcomes; questionnaire; validation
Urology. 2006 Aug;68(2 Suppl):9-16
16908336
J Clin Oncol. 2007 Nov 10;25(32):5121-7
17991931
J Natl Cancer Inst. 2014 Sep 29;106(9):
25265940
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
8433390
J Pain Symptom Manage. 2014 Sep;48(3):411-50
24703941
Ann Oncol. 2009 Dec;20(12):1905-6
19934250
J Am Stat Assoc. 1948 Dec;43(244):572-4
18123073
JAMA Oncol. 2015 Nov;1(8):1051-9
26270597
J Natl Cancer Inst. 2014 Jul 08;106(7):
25006191
J Natl Cancer Inst. 2011 Dec 21;103(24):1808-10
22157639
Psychol Bull. 1959 Mar;56(2):81-105
13634291
Eur J Oncol Nurs. 2015 Feb;19(1):66-74
25190633
Biometrics. 1977 Mar;33(1):159-74
843571
Bone Marrow Transplant. 2006 Feb;37(4):393-401
16415901